These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27145331)

  • 1. Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
    Jokubaitis VG; Spelman T; Kalincik T; Lorscheider J; Havrdova E; Horakova D; Duquette P; Girard M; Prat A; Izquierdo G; Grammond P; Van Pesch V; Pucci E; Grand'Maison F; Hupperts R; Granella F; Sola P; Bergamaschi R; Iuliano G; Spitaleri D; Boz C; Hodgkinson S; Olascoaga J; Verheul F; McCombe P; Petersen T; Rozsa C; Lechner-Scott J; Saladino ML; Farina D; Iaffaldano P; Paolicelli D; Butzkueven H; Lugaresi A; Trojano M;
    Ann Neurol; 2016 Jul; 80(1):89-100. PubMed ID: 27145331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
    J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
    Portaccio E; Ghezzi A; Hakiki B; Sturchio A; Martinelli V; Moiola L; Patti F; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; De Luca G; Paolicelli D; Marrosu MG; Comi G; Trojano M; Amato MP;
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):845-50. PubMed ID: 24403285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early versus later treatment start in multiple sclerosis: a register-based cohort study.
    Chalmer TA; Baggesen LM; Nørgaard M; Koch-Henriksen N; Magyari M; Sorensen PS;
    Eur J Neurol; 2018 Oct; 25(10):1262-e110. PubMed ID: 29847005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab in the pediatric MS population: results of the Italian registry.
    Ghezzi A; Moiola L; Pozzilli C; Brescia-Morra V; Gallo P; Grimaldi LM; Filippi M; G GC;
    BMC Neurol; 2015 Sep; 15():174. PubMed ID: 26407848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
    He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
    Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    Raffel J; Gafson AR; Dahdaleh S; Malik O; Jones B; Nicholas R
    PLoS One; 2017; 12(1):e0169546. PubMed ID: 28081190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
    Kalincik T; Manouchehrinia A; Sobisek L; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Girard M; Prat A; Duquette P; Grammond P; Sola P; Hupperts R; Grand'Maison F; Pucci E; Boz C; Alroughani R; Van Pesch V; Lechner-Scott J; Terzi M; Bergamaschi R; Iuliano G; Granella F; Spitaleri D; Shaygannejad V; Oreja-Guevara C; Slee M; Ampapa R; Verheul F; McCombe P; Olascoaga J; Amato MP; Vucic S; Hodgkinson S; Ramo-Tello C; Flechter S; Cristiano E; Rozsa C; Moore F; Luis Sanchez-Menoyo J; Laura Saladino M; Barnett M; Hillert J; Butzkueven H;
    Brain; 2017 Sep; 140(9):2426-2443. PubMed ID: 29050389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Stewart T; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Duquette P; Girard M; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Shaygannejad V; Hupperts R; Alroughani R; Oreja-Guevara C; Pucci E; Boz C; Lechner-Scott J; Bergamaschi R; Van Pesch V; Iuliano G; Ramo C; Taylor B; Slee M; Spitaleri D; Granella F; Verheul F; McCombe P; Hodgkinson S; Amato MP; Vucic S; Gray O; Cristiano E; Barnett M; Sanchez Menoyo JL; van Munster E; Saladino ML; Olascoaga J; Prevost J; Deri N; Shaw C; Singhal B; Moore F; Rozsa C; Shuey N; Skibina O; Kister I; Petkovska-Boskova T; Ampapa R; Kermode A; Butzkueven H; Jokubaitis V; Kalincik T;
    Mult Scler; 2017 Feb; 23(2):266-276. PubMed ID: 27055805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis.
    De Meo E; Bonacchi R; Moiola L; Colombo B; Sangalli F; Zanetta C; Amato MP; Martinelli V; Rocca MA; Filippi M
    Ann Neurol; 2021 May; 89(5):1011-1022. PubMed ID: 33598931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
    Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
    Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early clinical markers of aggressive multiple sclerosis.
    Malpas CB; Manouchehrinia A; Sharmin S; Roos I; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Eichau S; Bergamaschi R; Sola P; Ferraro D; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Grand'Maison F; Ozakbas S; Van Pesch V; Granella F; Hupperts R; Pucci E; Boz C; Sidhom Y; Gouider R; Spitaleri D; Soysal A; Petersen T; Verheul F; Karabudak R; Turkoglu R; Ramo-Tello C; Terzi M; Cristiano E; Slee M; McCombe P; Macdonell R; Fragoso Y; Olascoaga J; Altintas A; Olsson T; Butzkueven H; Hillert J; Kalincik T
    Brain; 2020 May; 143(5):1400-1413. PubMed ID: 32386427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.